Skip to main content
SpringerLink
Log in

House dust mite sublingual tablets (Actair®): a guide to their use as allergy immunotherapy for house dust mite-induced allergic rhinitis

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

House dust mite (HDM) allergen extract sublingual tablets (Actair®) are a valuable option to reduce allergy symptoms in patients with HDM-induced allergic rhinitis. Allergy immunotherapy (AIT) with 300 index of reactivity (IR) Actair® reduced the symptoms of allergic rhinitis in placebo-controlled natural-field and environmental exposure challenge chamber trials. Significant beneficial effects with 300 IR Actair® relative to placebo were shown as early as 2 months after the initiation of treatment, with efficacy being continuously maintained during the rest of the 1-year AIT period, as well as during a subsequent AIT-free year. Precautions should be followed to minimize the risk of systemic and local allergic reactions inherent to AIT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Batard T, Baron-Bodo V, Martelet A, et al. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy. Allergy. 2016;71(2):220–9.

    Article  CAS  PubMed  Google Scholar 

  2. Moingeon P. Progress in the development of specific immunotherapies for house dust mite allergies. Expert Rev Vaccines. 2014;13(12):1463–73.

    Article  CAS  PubMed  Google Scholar 

  3. Calderon MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38–48.

    Article  PubMed  Google Scholar 

  4. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(2 Suppl):S12–6.

    Article  PubMed  Google Scholar 

  5. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.

    Article  PubMed  Google Scholar 

  6. Braido F, Arcadipane F, Marugo F, et al. Allergic rhinitis: current options and future perspectives. Curr Opin Allergy Clin Immunol. 2014;14(2):168–76.

    Article  CAS  PubMed  Google Scholar 

  7. Brehler R, Klimek L, Kopp MV, et al. Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int. 2013;110(9):148–58.

    PubMed  PubMed Central  Google Scholar 

  8. Zuberbier T, Lotvall J, Simoens S, et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69(10):1275–9.

    Article  CAS  PubMed  Google Scholar 

  9. Linneberg A, Henrik Nielsen N, Frølund L, et al. the link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002;57(11):1048–52.

    Article  CAS  PubMed  Google Scholar 

  10. Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049–57.

    Article  PubMed  Google Scholar 

  11. Okubo K, Kurono Y, Fujieda S, et al. Japanese guidelines for allergic rhinitis 2014. Allergol Int. 2014;63(3):357–75.

    Article  CAS  PubMed  Google Scholar 

  12. Calderon MA, Kleine-Tebbe J, Linneberg A, et al. House dust mite respiratory allergy: an overview of current therapeutic strategies. J Allergy Clin Immunol Pract. 2015;3(6):843–55.

    Article  PubMed  Google Scholar 

  13. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma and Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–96.

    Article  PubMed  Google Scholar 

  14. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Biagtan M, Viswanathan R, Bush RK. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? Curr Allergy Asthma Rep. 2014;14(12):482.

    Article  PubMed  Google Scholar 

  16. Bahceciler N, Babayigit Hocaoglu A, Galip N. A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (Actair). Expert Rev Vaccines. 2014;13(12):1427–38.

    Article  CAS  PubMed  Google Scholar 

  17. Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67(3):302–11.

    Article  CAS  PubMed  Google Scholar 

  18. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;1(3):228–41.

    Article  PubMed  Google Scholar 

  19. Lyseng-Williamson KA. Standardized sublingual allergen extract solution (Staloral®): a guide to its use as allergen-specific immunotherapy. Drugs Ther Perspect. 2014;30(12):401–10.

    Article  Google Scholar 

  20. Actair® house dust mite 100 IR and 300 IR sublingual tablets: Japanese prescribing information. Osaka: Shiongoi Co., Ltd.; 2016.

  21. Actair® 100 IR and 300 IR sublingual tablets: Australian product information. Warriewood: Stallergenes Australia Pty Ltd; 2016.

  22. Roux M, Devillier P, Yang WH, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: results of a dose-ranging study in an environmental exposure chamber. J Allergy Clin Immunol. In press.

  23. Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(6):1608–14 e6.

  24. Demoly P, Passalacqua G, Calderon MA, et al. Choosing the optimal dose in sublingual immunotherapy: rationale for the 300 index of reactivity dose. Clin Transl Allergy. 2015;5:44. doi:10.1186/s13601-015-0088-1.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Fujita H, Soyka MB, Akdis M, et al. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012;2(1):2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Baron-Bodo V, Batard T, Nguyen H, et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clin Exp Allergy. 2012;42(10):1510–8.

    Article  CAS  PubMed  Google Scholar 

  27. Demoly P, Meziane L, Le Gall M, et al. Safety and tolerability of house dust mite tablets in sublingual immunotherapy [abstract no. 494]. J Allergy Clin Immunol. 2008;121(2 Suppl 1):S128.

    Article  Google Scholar 

  28. Demoly P, Le Gall M, Roux M, et al. Safety and tolerability of high doses of sublingual tablet of house dust mite allergen extracts in subjects with house dust mite-associated respiratory allergy [abstract no. 1095]. Allergy. 2015;70(Suppl 101):452.

    Google Scholar 

  29. Roux M, Patel P, Viatte A, et al. Safety of high doses of sublingual tablets of house dust mite allergen extracts in adolescents with allergic rhinitis [abstract no. 1789]. Allergy. 2014;69(Suppl 99):613.

    Google Scholar 

  30. Zeldin RK, Le Gall M, Rodriguez P, et al. Safety and tolerability of sublingual tablets of house dust mite allergen extracts: a phase I study in adults with house dust mite-associated allergic asthma [abstract no. A4267]. Am J Respir Crit Care Med. 2015;191 (Abstract Issue).

  31. Data on file. Osaka: Shionogi Co. Ltd.; 2015.

  32. Iglesias-Cadarso A, Hernández-Weigand P. Risk factors for systemic reactions to allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2011;11(6):579–85.

    Article  CAS  PubMed  Google Scholar 

  33. Radulovic S, Wilson D, Calderon M, et al. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740–52.

    Article  CAS  PubMed  Google Scholar 

  34. Zeldin RK, Bergmann KC, Okamoto Y, et al. Safety of the 300IR and 500IR doses of sublingual tablet of house dust mite allergen extracts (STG320) in subjects with house dust mite-associated allergic rhinitis [abstract no. P253]. Ann Allergy Asthma Immunol. 2015;115(5 Suppl):A111.

    Google Scholar 

  35. Zeldin RK, Le Gall M, Rodriguez P, et al. High doses of sublingual tablets of house dust mite allergen extracts: lung function assessment in a phase I study in adults with mite-associated allergic asthma [abstract no. PA4018]. Eur Respir J. 2015;46(Suppl 59):PA4018.

    Article  Google Scholar 

  36. Roux M, Viatte A, Zeldin RK. Safety of a sublingual tablet of house dust mite allergen extracts in an environmental exposure chamber study [abstract no. 867]. J Allergy Clin Immunol. 2015;135(2):AB266.

    Article  Google Scholar 

  37. Roux M, Yang WH, Devillier P, et al. Safety of the sublingual tablet of house dust mite allergen extracts in an environmental exposure chamber study: focus on asthma-related symptoms [abstract no. P267]. Ann Allergy Asthma Immunol. 2014;113(5 Suppl):A100.

    Google Scholar 

Download references

Acknowledgments

The manuscript was reviewed by: K.-C. Bergmann, Allergy-Centre-Charité, Charité- Universitätsmedizin Berlin, Berlin, Germany; F. Horak, Vienna Challenge Chamber Institute for Allergy Research, Vienna, Austria; C. Incorvaia, Allergy/Pulmonary Rehabilitation Unit, Istituti Clinici di Perfezionamento Hospital, Milan, Italy; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India; R. B. Shah, GMERS Medical College and Hospital, Gandhinagar, Gujarat, India. During the peer review process, the manufacturer of Actair® was offered an opportunity to comment on the article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. House dust mite sublingual tablets (Actair®): a guide to their use as allergy immunotherapy for house dust mite-induced allergic rhinitis. Drugs Ther Perspect 32, 219–225 (2016). https://doi.org/10.1007/s40267-016-0305-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0305-6

Keywords

Search

Navigation